Yahoo! Finance: ITMN News

Medicines Co. Buys Heart Drug From Pfizer: BioBuzz (at TheStreet.com)

Wed, 23 Dec 2009 12:59:52 Etc/GMT

Anadys hepatitis C drug meets key study goals (AP)

Thu, 17 Dec 2009 16:15:48 Etc/GMT

Anadys Pharmaceuticals Inc. said Thursday its experimental hepatitis C drug is meeting key goals in a midstage clinical trial.

Gilead's Phase 3 Train Wreck (at Motley Fool)

Wed, 16 Dec 2009 20:00:04 Etc/GMT

Achillion shares rise on hepatitis C drug data (AP)

Wed, 16 Dec 2009 19:33:53 Etc/GMT

Shares of Achillion Pharmaceuticals Inc. surged Wednesday after the company said its hepatitis C drug candidate showed positive "proof-of-concept" results, while meeting safety and tolerability goals in an early-stage study.

Five Biotech Events to Watch in 2010 (at TheStreet.com)

Wed, 16 Dec 2009 15:23:40 Etc/GMT

Five Biotech Events to Watch in 2010 (TheStreet.com)

Wed, 16 Dec 2009 15:23:40 Etc/GMT

InterMune to Present at Deutsche Bank Biotech Confab (PR Newswire)

Fri, 11 Dec 2009 21:00:00 Etc/GMT

InterMune, Inc. today announced that Steve Porter, M.D., Chief Medical Officer of InterMune, will present at the 2009 DB-Biotech Boston Confab on December 15, 2009 at 9:30 a.m. EST.

Bernanke's Double Edged Sword and 3 Shortable PowerRatings Stocks (TradingMarkets.com)

Mon, 7 Dec 2009 15:38:47 Etc/GMT

Are interest rate worries or Bernanke's next move weighing on your stock picking strategy? Try this highly effective 3 step system to locate stocks likely to make moves even in this overbought market.

Less Toxic Monoclonal Antibodies And Increased Patent Protection For Biologics Creates Multiple Positive Investment Scenarios In Biotechnology Sector (Wall Street Transcript)

Sat, 28 Nov 2009 15:23:00 Etc/GMT

67 WALL STREET, New York - November 28, 2009 - The Wall Street Transcript has recently published its Q4 2009 Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

[$$] Activity Jumps in Biotech and Drug Firms (at The Wall Street Journal Online)

Wed, 18 Nov 2009 02:33:20 Etc/GMT

[$$] Pacific Sunwear and Sunpower Fall (at The Wall Street Journal Online)

Wed, 18 Nov 2009 02:29:33 Etc/GMT

Biotech Stocks: Alkermes gains; Cerus, InterMune tumble (at MarketWatch)

Tue, 17 Nov 2009 19:04:00 Etc/GMT

Drug stocks dip in afternoon action, while shares of Alkermes gain on positive news about two of its substance-abuse therapies.

InterMune shares fall on change in hepatitis study (AP)

Tue, 17 Nov 2009 16:58:58 Etc/GMT

Shares of InterMune Inc. fell Tuesday after the biotechnology company said it would discontinue a high-dose of its experimental Hepatitis C treatment in a study because of potential liver damage.

Isis Cholesterol Drug Effective, but Safety a Worry: BioBuzz (at TheStreet.com)

Tue, 17 Nov 2009 15:56:33 Etc/GMT

INTERMUNE INC Files SEC form 8-K, Other Events (EDGAR Online)

Tue, 17 Nov 2009 15:29:47 Etc/GMT

InterMune Hep C Drug Hit With Liver Tox Worry: BioBuzz (at TheStreet.com)

Tue, 17 Nov 2009 14:11:12 Etc/GMT

InterMune Announces Modification to On-Going Phase 2b Study of ITMN-191 in Patients with Chronic HCV Infection (PR Newswire)

Tue, 17 Nov 2009 13:30:00 Etc/GMT

InterMune, Inc. today announced that the on-going Phase 2b study conducted by Roche of ITMN-191 combined with standard of care PEGASYS® and COPEGUS® in HCV treatment-naive patients has been modified.

InterMune, Inc. Q3 2009 Earnings Call Transcript (at Seeking Alpha)

Tue, 10 Nov 2009 20:07:10 Etc/GMT

Doc Offers Top Hep C Drug Picks: BioBuzz (at TheStreet.com)

Mon, 9 Nov 2009 18:54:15 Etc/GMT

New Star Analyst Rankings for InterMune, Inc. (StarMine)

Sun, 8 Nov 2009 14:19:53 Etc/GMT